Regentis Biomaterials Ltd. (RGNT)

Regentis Biomaterials Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec 31, 2025	Dec 31, 2024
Selling, General & Admin	6.64	0.71
Research & Development	0.33	-1.64
Total Operating Expenses	6.97	-0.93
Operating Income	-6.97	0.93
Total Non-Operating Income (Expense)	-6.68	3.87
Pretax Income	-13.65	4.8
Net Income	-13.65	4.8
Net Income to Common	-13.65	4.8
Shares Outstanding (Basic)	1	1
Shares Outstanding (Diluted)	1	1
EPS (Basic)	-24.16	1.72
EPS (Diluted)	-24.16	1.72
Shares Outstanding	5.18	0.16
Free Cash Flow	-1.38	-0.64
Free Cash Flow Per Share	-2.43	-1.13
EBITDA	-6.97	0.93
EBIT	-6.97	0.93

SEC Filings: 10-K · 10-Q

Data Source: Fiscal.ai Last updated: Dec 31, 2025

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

May 30, 2026

Data Sources Report a data error